Clik here to view.
Takeda Announces European Medicines Agency Acceptance of Ixazomib’s Marketing...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application...
View ArticleClik here to view.
Technavio Says the Increase in Exports Will Boost the Turmeric Market in...
LONDON Technavio, a tech-focused research firm, has published a new report on the turmeric market in India which is expected to grow at a CAGR of more than 1% from 2015-2019. According to the latest...
View ArticleClik here to view.
武田薬品、欧州医薬品庁が再発性／難治性の多発性骨髄腫患者に対するイキサゾミブの販売承認申請を受理したと発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ）– 武田薬品工業株式会社(TSE:...
View ArticleClik here to view.
武田宣布，欧洲药品管理局已受理ixazomib用于复发/难治多发性骨髓瘤患者的市场营销授权申请
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE: 4502) 今天宣布，欧洲药品管理局(EMA)已受理ixazomib用于复发/难治多发性骨髓瘤患者的市场营销授权申请(MAA)，ixazomib是口服蛋白酶体抑制剂类研究药物。7月23日，ixazomib进入EMA人用药品委员会(CHMP)的加速审理，加速审理适用于具有重大公共卫生意义的药品，尤其是创新治疗药物。...
View ArticleClik here to view.
Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology
GUANGZHOU, China & SAN DIEGO Burning Rock and Illumina, Inc. (NASDAQ: ILMN) today announced they have entered into an agreement whereby Burning Rock will develop advanced clinical applications...
View ArticleClik here to view.
DynoSense Closes $9.4 Million Series A Funding Round
SUNNYVALE, Calif. Digital health innovator DynoSense has announced that it has closed a $9.4 million Series A funding round, with participation from WI Harper Group; JKOM Cloud Health Technology Co;...
View ArticleClik here to view.
Amneal Announces New Biosciences Unit with Charles Lucarelli as President
BRIDGEWATER, N.J. Amneal today announced the creation of Amneal Biosciences, a wholly-owned subsidiary of Amneal Pharmaceuticals LLC (www.amneal.com). Amneal Biosciences will focus exclusively on...
View ArticleClik here to view.
巴西A.C.Camargo癌症中心采用Masimo SpHb用于血红蛋白的无创连续监测
瑞士纳沙泰尔 (美国商业资讯)–Masimo (NASDAQ: MASI)今天宣布，巴西圣保罗A.C.Camargo癌症中心 已安装Masimo的无创连续血红蛋白(SpHb®)技术来监测手术患者。...
View ArticleClik here to view.
ブラジルのACカマルゴがんセンターが非侵襲的・連続的ヘモグロビン測定でマシモのSpHb技術を導入
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、ブラジル・サンパウロのACカマルゴがんセンターが外科患者をモニタリングするためにマシモの非侵襲的・連続的ヘモグロビン（SpHb®）測定技術を導入したと発表しました。...
View ArticleClik here to view.
Transgenomic Adds Asia Distributors for Its ICEme™ Kits That Enable Liquid...
OMAHA, Neb. Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing precision medicine through advanced diagnostic tests and clinical and research services, today announced the...
View ArticleClik here to view.
First Australian and Asia/Pacific Hospital to Demonstrate Commitment to New...
MELBOURNE, Australia Alfred Health Radiation Oncology (AHRO), based at The William Buckland Radiotherapy Centre, announced today that it has become the first cancer centre in the Asia and Pacific...
View ArticleClik here to view.
3D Printing and Additive Manufacturing Market Size, Shares, Analysis,...
ALBANY, N.Y. ResearchMoz has added a report titled “Global and China 3D Printing and Additive Manufacturing Market 2015-2025: Industry Analysis, Shares, Size, Trends, Growth, Technologies, Key...
View ArticleClik here to view.
US FDA Approves Initiation of ViroMed’s VM202 for Phase III Clinical Study of...
ATLANTA ViroMed Co., Ltd. (084990:KS, KOSDAQ) today announced that the company has received an approval from the US FDA to launch a pivotal Phase III clinical trial utilizing VM202, a proprietary...
View ArticleClik here to view.
Clik here to view.
大日本住友製薬との共同研究における最初のマイルストーン達成に関するお知らせ
スコットランド・ダンディー ex scientia Ltd.（以下、「エクセンシア」）は大日本住友製薬株式会社（以下、「大日本住友製薬」）との初年度の共同研究において、高次評価試験を進めるに値する最適化化合物を取得したことを発表します。...
View ArticleClik here to view.
ASE Foundation Selects Mindray as Exclusive Corporate Sponsor of Its...
HA NOI, Vietnam Mindray, one of the world’s leading developers of cardiac ultrasound technologies, is proud to announce that it was exclusively selected for the American Society of Echocardiography...
View ArticleClik here to view.
NovaBay Pharmaceuticals Signs Distribution Agreement to Make Avenova...
EMERYVILLE, Calif. NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care...
View ArticleClik here to view.
Enrollment Begins in Cytori Phase III/Pivotal ADRESU Urinary Incontinence Trial
SAN DIEGO Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced that the first patient has been enrolled and treated in the ADRESU trial, a late phase, physician-initiated Japanese clinical trial to...
View ArticleClik here to view.
Novocure Announces Optune Now Available at more than 200 Leading Cancer...
NEW YORK Novocure announced today that more than 200 treatment centers in the United States have been certified to prescribe Optune to patients with recurrent glioblastoma (GBM). GBM is the most...
View ArticleClik here to view.
AstraZeneca Presents Further Evidence for the Potential of AZD9291 in...
LONDON AstraZeneca today announced updated data on AZD9291 in first-line patients with epidermal growth factor receptor mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC) and...
View Article